← Browse by Condition
Medical Condition
high grade b cell lymphoma with myc and bcl2 and or bcl6 rearrangements
Total Trials
4
Recruiting Now
4
Trial Phases
Phase 1, Phase 2, Phase 1, Phase 2
Lymphoma trials span diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, Hodgkin lymphoma, mantle cell lymphoma, and T-cell lymphomas β€” each with distinct biology and treatment response. CAR-T cell therapy has established a new standard in relapsed/refractory DLBCL, and trials now aim to move this approach earlier in the treatment sequence.
Active trials evaluate bispecific antibodies (mosunetuzumab, epcoritamab, glofitamab), next-generation CAR-T cell products (CD19/CD22 dual targets, BCMA-targeting), BTK inhibitors in B-cell lymphomas, and total metabolic volume on PET as a predictive biomarker for treatment adaptation.
Frequently Asked Questions — high grade b cell lymphoma with myc and bcl2 and or bcl6 rearrangements Clinical Trials
How many clinical trials are currently recruiting for high grade b cell lymphoma with myc and bcl2 and or bcl6 rearrangements?
ClinicalMetric currently tracks 4 actively recruiting clinical trials for high grade b cell lymphoma with myc and bcl2 and or bcl6 rearrangements, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 4. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for high grade b cell lymphoma with myc and bcl2 and or bcl6 rearrangements?
high grade b cell lymphoma with myc and bcl2 and or bcl6 rearrangements research spans Phase 1 (2 trials), Phase 2 (3 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a high grade b cell lymphoma with myc and bcl2 and or bcl6 rearrangements clinical trial?
Eligibility criteria for high grade b cell lymphoma with myc and bcl2 and or bcl6 rearrangements trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1 2
Phase 2 3
Top Sponsors
2 trials
1 trial
1 trial
Recruiting Clinical Trials
NCT04231877 Phase 1
Recruiting
Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma
Enrollment
56 pts
Location
United States
Sponsor
University of Washington
NCT07097363 Phase 2
Recruiting
Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma
Enrollment
18 pts
Location
United States
Sponsor
University of Washington
NCT05890352 Phase 2
Recruiting
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
Enrollment
227 pts
Location
United States
Sponsor
SWOG Cancer Research Network
NCT01371630 Phase 1, Phase 2
Recruiting
Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia
Enrollment
276 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology